TAMPELLINI, MARCO
TAMPELLINI, MARCO
ONCOLOGIA
Changes in body composition after androgen deprivation therapy (ADT) in prostate cancer patients. Relationship with disease outcome
2008-01-01 A. Berruti; F. Vana; M. Tucci; A. Mosca; L. Russo; G. Gorzegno; A. Saini; P. Perotti; M. Tampellini; L. Dogliotti
Chirurgia delle metastasi polmonari da carcinoma colo-rettale: una serie di 171 pazienti.
2014-01-01 Luca Errico; Elena Lisi; Elena Asteggiano; Matteo Gagliasso; Nicola Liberato; Corrado Novello; Marco Tampellini; Francesco Ardissone
Chronomodulated delivery schedule of Oxaliplatin (OHP), 5-Fluorouracil and Folinic Acid (FFL4/10) allows to increase significantly dose intensity rate of OHP based schedule: 2 years experience in gastrointestinal cancers
2004-01-01 Masseroni S; Pirovano M; Nasisi A; Biffi A; Romanelli A; Sestini S; Valsecchi R; Martignoni G; Tabiadon D; Tampellini M
Circadian rhythm of bone turnover markers in breast cancer patients with bone metastases and in control subjects
2005-01-01 D. G. Generali; S. Tedoldi; M. Tampellini; A. Berruti; M. Torta; S. Bonardi; A. Bottini; M. Tucci; M. Milani; A. Angeli; L. Dogliotti
CIRCADIAN RHYTHM OF BONE TURNOVER MARKERS INBREAST CANCER PATIENTS WITH METASTATIC BONE DISEASE ANDIN CONTROL SUBJECTS
2004-01-01 Daniele Generali; Sara Tedoldi; Alberto Bottini; Alfredo Berruti; Marco Tampellini; Marcello Tucci; Giovanni Allevi; Mirella Torta; Simone Bonardi; Manuela Milani; Sergio Aguggini; Alberto Angeli; Luigi Dogliotti
Circadian rhythm of breakthrough cancer pain.
2011-01-01 A. Saini; M. Tucci; K. Bouraouia; P. Ghio; M. Tampellini; P. M. Furlan; L. Ostacoli; L. Dogliotti; A. Berruti
Effect of zoledronic acid (Z) treatment based on serum parathyroid hormone (PTH) levels in patients (pts) with malignant bone disease.
2006-01-01 Berruti A; Dogliotti L; Tampellini M; Lipton A; Hirsh V; Saad F; Liati P; Shirina N; Cook R; Hei YL
GENDER-DEPENDENT OPTIMAL SCHEDULING OFCANCER CHRONOTHERAPEUTICS
2006-01-01 F. Levi; S. Giacchetti; G. Bjarnason; C. Focan; D. Genet; S. Iacobelli; M. Tampellini; R. Smaaland; T. Gorlia; C. Garufi
Increased antiresorptive activity of zoledronic acid (Z) administered in the night as compared to morning administration in breast cancer (BC) patients with bone metastases.
2006-01-01 Bottini A; Generali D; Berruti A; Tampellini M; Torta M; Tedoldi S; Bonardi S; Tucci M; Gorzegno G; Dogliotti L
INCREASED NUMBER OF NEUROENDOCRINE CELLS IN METASTATIC COLORECTAL ADENOCARCINOMA FOLLOWING CHEMO/RADIOTHERAPY
2007-01-01 Snezana Andrejevic-Blant; Marco Tampellini; Luisella Righi; Irene Alabiso; Veronica Tavaglione; Marco Volante; Luigi Dogliotti; Mauro Papotti; Valerio Marci
LONG-TERM SURVIVAL OF PATIENTS WITH RESECTION OF PULMONARY METASTASES FROM COLORECTAL NEOPLASMS AS COMPARED TO NOT RESECTED ONES. A RETROSPECTIVE STUDY ON PATIENTS FOLLOWED FROM THE TIME OF FIRST RECURRENCE
2011-01-01 Marco Tampellini; Azzurra Ottone; Elisa Bellini; Irene Alabiso; Francesco Leone; Stefania Miraglia; Oscar Alabiso; Massimo Aglietta; Luigi Dogliotti
NATURAL HISTORY OF MALIGNANT BONE DISEASE IN COLORECTAL CANCER: FINAL RESULTS OF A LARGE ITALIAN "BONE METASTASES" SURVEY
2010-01-01 Santini D; Tampellini M; Barni S; Silvestris N; Maiello E; Calipari N; Ibrahim T; Catalano V; Vincenzi B; Tonini G
Natural history of malignant bone disease in colorectal cancer: Final results of a large Italian “bone metastases” survey
2011-01-01 D. Santini; S. Barni; M. Tampellini; N. Silvestris; E. Maiello; N. Calipari; T. Ibrahim; V. Catalano; B. Vincenzi; G. Tonini
PHASE II TRIAL OF PANITUMUMAB IN COMBINATION WITH OXALIPLATIN AND CAPECITABINE CHEMOTHERAPY AS 1ST LINE THERAPY IN PATIENTS WITH COLORECTAL CANCER AND ADVANCED LIVER METASTASES: THE METAPAN STUDY
2012-01-01 Leone F; Marino D; Artale S; Cagnazzo C; Cascinu S; Martoni AA; Sobrero A; Tampellini M; Siena S; Aglietta M
Predictive factors for skeletal complications in prostate cancer patients with hormone refractory disease
2005-01-01 M. Tucci; A. Berruti; A. Mosca; F. Vana; G. La Manna; L. Russo; M. Poggio; R. Bitossi; G. Gorzegno; M. Tampellini; A. Saini
Prognostic factors in advanced colorectal carcinoma: A multifactorial analysis
2005-01-01 L. Forti; S. Miraglia; E. Bertona; V. Rossi; D. Rondonotti; M. Tampellini; G. Porcile; O. Alabiso
Role of surgical resection in colorectal lung metastases: analysis of 137 patients
2009-01-01 Borasio P; Gisabella M; Billè A; Righi L; Tampellini M; Ardissone F.
Survival of lung surgery patients with pulmonary metastases from colonic neoplasms
2008-01-01 M. Tampellini; I. Alabiso; A. Ottone; S. Miraglia; L. Forti; E. Bertona; C. M. Sculli; E. Bellini; O. Alabiso; L. Dogliotti
TGFalfa, EGFR and p70S6K expression in aggressive colorectal cancer (CRC)
2006-01-01 M. Tampellini; M. Longo; S. Cappia; E. Bacillo; M. Brizzi; R. Bitossi; C. M. Sculli; I. Alabiso; L. Dogliotti; M. Papotti
The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load.
2006-01-01 A Dovio; D Generali; A Berruti; M Tampellini; S Tedoldi; S Bonardi; M Tucci; G Allevi; S Aguggini; M Milani; A Bottini; L Dogliotti; A Angeli
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Changes in body composition after androgen deprivation therapy (ADT) in prostate cancer patients. Relationship with disease outcome | 2008 | A. Berruti; F. Vana; M. Tucci; A. Mosca; L. Russo; G. Gorzegno; A. Saini; P. Perotti; M. Tampellini; L. Dogliotti | |
| Chirurgia delle metastasi polmonari da carcinoma colo-rettale: una serie di 171 pazienti. | 2014 | Luca Errico; Elena Lisi; Elena Asteggiano; Matteo Gagliasso; Nicola Liberato; Corrado Novello; Marco Tampellini; Francesco Ardissone | |
| Chronomodulated delivery schedule of Oxaliplatin (OHP), 5-Fluorouracil and Folinic Acid (FFL4/10) allows to increase significantly dose intensity rate of OHP based schedule: 2 years experience in gastrointestinal cancers | 2004 | Masseroni S; Pirovano M; Nasisi A; Biffi A; Romanelli A; Sestini S; Valsecchi R; Martignoni G; Tabiadon D; Tampellini M | |
| Circadian rhythm of bone turnover markers in breast cancer patients with bone metastases and in control subjects | 2005 | D. G. Generali; S. Tedoldi; M. Tampellini; A. Berruti; M. Torta; S. Bonardi; A. Bottini; M. Tucci; M. Milani; A. Angeli; L. Dogliotti | |
| CIRCADIAN RHYTHM OF BONE TURNOVER MARKERS INBREAST CANCER PATIENTS WITH METASTATIC BONE DISEASE ANDIN CONTROL SUBJECTS | 2004 | Daniele Generali; Sara Tedoldi; Alberto Bottini; Alfredo Berruti; Marco Tampellini; Marcello Tucci; Giovanni Allevi; Mirella Torta; Simone Bonardi; Manuela Milani; Sergio Aguggini; Alberto Angeli; Luigi Dogliotti | |
| Circadian rhythm of breakthrough cancer pain. | 2011 | A. Saini; M. Tucci; K. Bouraouia; P. Ghio; M. Tampellini; P. M. Furlan; L. Ostacoli; L. Dogliotti; A. Berruti | |
| Effect of zoledronic acid (Z) treatment based on serum parathyroid hormone (PTH) levels in patients (pts) with malignant bone disease. | 2006 | Berruti A; Dogliotti L; Tampellini M; Lipton A; Hirsh V; Saad F; Liati P; Shirina N; Cook R; Hei YL | |
| GENDER-DEPENDENT OPTIMAL SCHEDULING OFCANCER CHRONOTHERAPEUTICS | 2006 | F. Levi; S. Giacchetti; G. Bjarnason; C. Focan; D. Genet; S. Iacobelli; M. Tampellini; R. Smaaland; T. Gorlia; C. Garufi | |
| Increased antiresorptive activity of zoledronic acid (Z) administered in the night as compared to morning administration in breast cancer (BC) patients with bone metastases. | 2006 | Bottini A; Generali D; Berruti A; Tampellini M; Torta M; Tedoldi S; Bonardi S; Tucci M; Gorzegno G; Dogliotti L | |
| INCREASED NUMBER OF NEUROENDOCRINE CELLS IN METASTATIC COLORECTAL ADENOCARCINOMA FOLLOWING CHEMO/RADIOTHERAPY | 2007 | Snezana Andrejevic-Blant; Marco Tampellini; Luisella Righi; Irene Alabiso; Veronica Tavaglione; Marco Volante; Luigi Dogliotti; Mauro Papotti; Valerio Marci | |
| LONG-TERM SURVIVAL OF PATIENTS WITH RESECTION OF PULMONARY METASTASES FROM COLORECTAL NEOPLASMS AS COMPARED TO NOT RESECTED ONES. A RETROSPECTIVE STUDY ON PATIENTS FOLLOWED FROM THE TIME OF FIRST RECURRENCE | 2011 | Marco Tampellini; Azzurra Ottone; Elisa Bellini; Irene Alabiso; Francesco Leone; Stefania Miraglia; Oscar Alabiso; Massimo Aglietta; Luigi Dogliotti | |
| NATURAL HISTORY OF MALIGNANT BONE DISEASE IN COLORECTAL CANCER: FINAL RESULTS OF A LARGE ITALIAN "BONE METASTASES" SURVEY | 2010 | Santini D; Tampellini M; Barni S; Silvestris N; Maiello E; Calipari N; Ibrahim T; Catalano V; Vincenzi B; Tonini G | |
| Natural history of malignant bone disease in colorectal cancer: Final results of a large Italian “bone metastases” survey | 2011 | D. Santini; S. Barni; M. Tampellini; N. Silvestris; E. Maiello; N. Calipari; T. Ibrahim; V. Catalano; B. Vincenzi; G. Tonini | |
| PHASE II TRIAL OF PANITUMUMAB IN COMBINATION WITH OXALIPLATIN AND CAPECITABINE CHEMOTHERAPY AS 1ST LINE THERAPY IN PATIENTS WITH COLORECTAL CANCER AND ADVANCED LIVER METASTASES: THE METAPAN STUDY | 2012 | Leone F; Marino D; Artale S; Cagnazzo C; Cascinu S; Martoni AA; Sobrero A; Tampellini M; Siena S; Aglietta M | |
| Predictive factors for skeletal complications in prostate cancer patients with hormone refractory disease | 2005 | M. Tucci; A. Berruti; A. Mosca; F. Vana; G. La Manna; L. Russo; M. Poggio; R. Bitossi; G. Gorzegno; M. Tampellini; A. Saini | |
| Prognostic factors in advanced colorectal carcinoma: A multifactorial analysis | 2005 | L. Forti; S. Miraglia; E. Bertona; V. Rossi; D. Rondonotti; M. Tampellini; G. Porcile; O. Alabiso | |
| Role of surgical resection in colorectal lung metastases: analysis of 137 patients | 2009 | Borasio P; Gisabella M; Billè A; Righi L; Tampellini M; Ardissone F. | |
| Survival of lung surgery patients with pulmonary metastases from colonic neoplasms | 2008 | M. Tampellini; I. Alabiso; A. Ottone; S. Miraglia; L. Forti; E. Bertona; C. M. Sculli; E. Bellini; O. Alabiso; L. Dogliotti | |
| TGFalfa, EGFR and p70S6K expression in aggressive colorectal cancer (CRC) | 2006 | M. Tampellini; M. Longo; S. Cappia; E. Bacillo; M. Brizzi; R. Bitossi; C. M. Sculli; I. Alabiso; L. Dogliotti; M. Papotti | |
| The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load. | 2006 | A Dovio; D Generali; A Berruti; M Tampellini; S Tedoldi; S Bonardi; M Tucci; G Allevi; S Aguggini; M Milani; A Bottini; L Dogliotti; A Angeli |